

STEMLINE THERAPEUTICS INC  
Form 8-K  
August 25, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **August 23, 2016**

**Stemline Therapeutics, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35619**  
(Commission File Number)

**45-0522567**  
(IRS Employer Identification  
No.)

**750 Lexington Avenue**  
**Eleventh Floor**  
**New York, New York 10022**

Edgar Filing: STEMLINE THERAPEUTICS INC - Form 8-K

(Address of Principal Executive Offices)

**(646) 502-2311**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act.
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
-

**Item 8.01 Other Events.**

On August 23, 2016, Stemline Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to SL-401, a targeted therapy directed to the interleukin-3 receptor (CD123), for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

A copy of the press release is being furnished as Exhibit 99.1 to this report.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Stemline Therapeutics, Inc.**  
(Registrant)

By

/s/ Kenneth Hoberman  
Kenneth Hoberman  
Chief Operating Officer

Date: August 25, 2016

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press release dated August 23, 2016.